Genprex (NASDAQ:GNPX – Get Free Report)’s share price traded down 2.8% during mid-day trading on Monday . The stock traded as low as $0.8306 and last traded at $0.8453. 378,736 shares were traded during mid-day trading, a decline of 71% from the average session volume of 1,289,422 shares. The stock had previously closed at $0.87.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genprex in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Genprex currently has a consensus rating of “Sell”.
Read Our Latest Report on Genprex
Genprex Trading Up 2.5%
Genprex (NASDAQ:GNPX – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter.
Institutional Trading of Genprex
Institutional investors and hedge funds have recently bought and sold shares of the company. Susquehanna International Group LLP increased its stake in Genprex by 11.7% during the 3rd quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after purchasing an additional 35,661 shares in the last quarter. Mayflower Financial Advisors LLC bought a new stake in Genprex during the 1st quarter valued at about $36,000. Finally, Manchester Financial Inc. bought a new stake in Genprex during the 1st quarter valued at about $36,000. 14.05% of the stock is currently owned by institutional investors.
Genprex Company Profile
Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.
In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.
Featured Articles
- Five stocks we like better than Genprex
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.
